BL-B01D1 是一种靶向 EGFR 和 HER3 的双特异性抗体-药物偶联物 (ADC)，由 EGFR/HER3 双特异性抗体 Izalontamab 通过可裂解接头 (Mc-Gly-Gly-Phe-Gly) 与新型 TOP-I 抑制剂 Deruxtecan 2-hydroxypropanamide 有效载荷连接而成。BL-B01D1 可结合肿瘤细胞表面的 EGFR 与 HER3，介导内吞作用并释放载荷，抑制拓扑异构酶 I (topoisomerase I)，阻断 DNA 复制与 RNA 合成，破坏 DNA 结构。BL-B01D1 可诱导细胞周期 S 期阻滞、细胞凋亡 (apoptosis)、抗体依赖的细胞介导的细胞毒性作用及肿瘤细胞死亡。BL-B01D1 可用于癌症研究。
| 生物活性 |
BL-B01D1 is a bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, formed by conjugating the EGFR/HER3 bispecific antibody Izalontamab to a novel TOP-I inhibitor payload Deruxtecan 2-hydroxypropanamide via a cleavable linker (Mc-Gly-Gly-Phe-Gly). BL-B01D1 binds to EGFR and HER3 on the surface of tumor cells, mediates endocytosis and releases the payload, inhibits topoisomerase I, blocks DNA replication and RNA synthesis, and disrupts DNA structure. BL-B01D1 induces cell cycle S-phase arrest, apoptosis, antibody-dependent cell-mediated cytotoxicity, and tumor cell death. BL-B01D1 can be used for cancer research. |
|---|---|
| 运输条件 |
Shipping with dry ice.
|
| 储存方式 |
-80°C, protect from light |
纯度： 98%
咨询热线：
400-881-9290
Data Sheet
